A Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess the Safety of Basaglar in Subjects With Type 2 Diabetes Mellitus in India
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 03 Sep 2021 Status changed from active, no longer recruiting to completed.
- 04 Aug 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2021 Planned End Date changed from 15 Jul 2021 to 29 Aug 2021.